Dual metalloprotease inhibitors: Mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidase

Journal of Medicinal Chemistry

Volumn 40, Issue 11, 1997, Pages 1570-1577

  Robl, Jeffrey A ^a   Sun, Chong Qing ^a   Stevenson, Jay ^a   Ryono, Denis E ^a   Simpkins, Ligaya M ^a   Cimarusti, Maria P ^a   Dejneka, Tamara ^a   Slusarchyk, William A ^a   Chao, Sam ^a   Stratton, Leslie ^a   Misra, Raj N ^a   Bednarz, Mark S ^a   Asaad, Magdi M ^a   Cheung, Hong Son ^a   Abboa Offei, Benoni E ^a   Smith, Patricia L ^a   Mathers, Parker D ^a   Fox, Maxine ^a   Schaeffer, Thomas R ^a   Seymour, Andrea A ^a   Trippodo, Nick C ^a   more..

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENKEPHALINASE INHIBITOR; FOSINOPRIL; METALLOPROTEINASE INHIBITOR; OMAPATRILAT; OXAZEPINE DERIVATIVE; THIAZEPINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG FORMULATION; DRUG POTENCY; DRUG SYNTHESIS; ESSENTIAL HYPERTENSION; MONKEY; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PLASMA RENIN ACTIVITY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SPONTANEOUSLY HYPERTENSIVE RAT;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; ATRIAL NATRIURETIC FACTOR; CARDIOVASCULAR AGENTS; CYCLIC GMP; ENZYME INHIBITORS; HEART FAILURE, CONGESTIVE; HYPERTENSION; MACACA FASCICULARIS; NEPRILYSIN; PYRIDINES; RATS; RENIN; SODIUM; THIAZEPINES;

EID: 17644438887     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm970041e     Document Type: Article

References (39)

1. (a) Lawton, G.; Paciorek, P. M.; Waterfall, J. F. The design and biological properties of ACE inhibitors. Advances in Drug Research; Academic Press Limited: New York, 1992; Vol. 23, pp 161-221.
2. (b) Salvetti, A. Newer ACE inhibitors: A look at the future. Drugs 1990, 40, 800-828.
3. (a) Roques, B. P.; Noble, F.; Dauge, V.; Fournie-Zaluski, M-C.; Beaumont, A. Neutral endopeptidase 24.11: Structure, inhibition, and experimental and clinical pharmacology. Pharmacol. Rev. 1993, 45, 87-146.
4. (b) Wilkins, M. R.; Unwin, R. J.; Kenny, A. J. Endopeptidae-24.11 and its inhibitors: Potential therapeutic agents for edematous disorders and hypertension. Kidney Int. 1993, 43, 273-285.
5. (c) Lang, C. C.; Choy, A-M. J.; Struthers, A. D. Atrial and brain natriuretic peptides: A dual natriuretic peptide system potentially involved in circulatory homeostasis. Clin. Sci. 1992, 83, 519-527.
6. (d) Lang, R. E.; Unger, T.; Ganten, D. Atrial natriuretic peptide: A new factor in blood pressure control. J. Hyperten. 1987, 5, 255-271.
7. (a) Margulies, K. B.; Perrella, M. A.; McKinley, L. J.; Burnett, J. Angiotensin inhibition potentiates the renal response to neutral endopeptidase inhibition in dogs with congestive heart failure. J. Clin. Invest. 1991, 88, 1636-1642.
8. (b) Seymour, A. A.; Swerdel, J. N.; Abboa-Offei, B. Antihypertensive activity during inhibition of neutral endopeptidase and angiotensin converting enzyme. J. Cardiovasc. Pharm. 1991, 17, 456-465.
9. (c) Seymour, A. A.; Swerdel, J. N.; Abboa-Offei, B. E. Antihypertensive activity during inhibition of neutral endopeptidase and angiotensin converting enzyme. J. Cardiovasc. Pharmacol. 1991, 17, 456-465.
10. (d) Seymour, A. A.; Asaad, M. M.; Lanoce, V. M.; Langenbacher, K. M.; Fennell, S. A.; Rogers, W. L. Systemic hemodynamics, renal function and hormonal levels during inhibition of neutral endopeptidase 3.4.24.11 and angiotensin-converting enzyme in conscious dogs with pacing-induced heart failure. J. Pharmacol. Exp. Ther. 1993, 266, 872-883.
11. (e) Trippodo, N. C.; Fox, M.; Natarajan, V.; Panchal, B. C.; Dorso, C. R.; Asaad, M. M. Combined inhibition of neutral endopeptidase and angiotensin converting enzyme in cardiomyopathic hamsters with compensated heart failure. J. Pharmacol. Exp. Ther. 1993, 267, 108-116.
12. (f) Pham, I.; Gonzalez, W.; El Amrani, A.-I. K.; Fournie-Zaluski, M.-C.; Philippe, M.; Laboulandine, I.; Roques, B. P.; Michel, J.-B. Effects of converting enzyme inhibitor and neutral endopeptidase inhibitor on blood pressure and renal function in experimental hypertension. J. Pharmacol. Exp. Ther. 1993, 265, 1339-1347.
13. (g) Seymour, A. A.; Asaad, M. M.; Smith, P. L.; Abboa-Offei, B. E.; Rogers, W. L.; Dorso, C. R. Effects of fosinoprilat or an angiotensin II (A II) antagonist on a neutral endopeptidase (NEP) inhibition in conscious renal hypertensive dogs. FASEB J. 1994, 8, A551.
14. (h) Trippodo, N. C.; Panchal, B. C.; Fox, M. Repression of angiotensin II and potentiation of bradykinin contribute to the synergistic effects of dual metalloprotease inhibition in heart failure. J. Pharmacol. Exper. Ther. 1995, 272, 1-9.
15. (a) Richards, A. M.; Wittert, G. A.; Espiner, E. A.; Yandle, T. G.; Ikram, H.; Frampton, C. Effect of inhibition of endopeptidase 24.11 on responses to angiotensin II in human volunteers. Circ. Res. 1992, 71, 1501-1507.
16. (b) O'Connell, J. E.; Jardine, A. G.; Davies, D. L.; McQueen, J.; Connell, J. M. C. Renal and hormonal effects of chronic inhibition of neutral endopeptidase (EC 3.4.24.11) in normal man. Clin. Sci. 1993, 85, 19-26.
17. (c) Richards, A. M.; Wittert, G. A.; Crozier, I. G.; Espiner, E. A.; Yandle, T. G.; Ikram, H.; Frampton, C. Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II. J. Hypertension 1993, 11, 407-416.
18. Robl, J. A.; Simpkins, L. M.; Stevenson, J.; Sun, C. Q.; Murugesan, N.; Barrish, J. C.; Asaad, M. M.; Bird, J. E.; Schaeffer, T. R.; Trippodo, N. R.; Petrillo, E. W.; Karanewsky, D. S. Dual metalloprotease inhibitors. I. Constrained peptidomimetics of mercaptoacyl dipeptides. BioorgMed. Chem. Lett. 1994, 4, 1789-1794.
19. For a representative set of leading references on mercaptoacyl dipeptides and dipeptide mimetics, see: (a) Robl, J. A.; Cimarusti, M. P.; Simpkins, L. M.; Brown, B. B.; Ryono, D. E.; Bird, J. E.; Asaad, M. M.; Schaeffer, T. R.; Trippodo, N. C. Dual metalloprotease inhibitors 6. Incorporation of bicyclic and substituted monocyclic azepinones as dipeptide surrogates in angiotensin-converting enzyme/neutral endopeptidase inhibitors. J. Med. Chem. 1996, 39, 494-502 and references therin. (b) Fink, C. A.; Carlson, J. E.; McTaggart, P. A.; Qiao, Y.; Webb, R.; Chatelain, R.; Jeng, A. Y.; Trapani, A. J. Mercaptoacyl dipeptides as orally active dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase. J. Med. Chem. 1996, 39, 3158-3168 and references therin. (c) Fournie-Zaluski, M.-C.; Coric, P.; Thery, V.; Gonzalez, W.; Meudal, H.; Turcaud, S.; Michel, J.-B.; Roques, B. P. Design of orally active dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme with long duration of action. J. Med. Chem. 1996, 39, 2594-2608 and references therein. (d) Flynn, G. A.; Beight, D. W.; Mehdi, S.; Koehl, J. R.; Giroux, E. L.; French, J. F.; Hake, P. W.; Dage, R. C. Application of a conformationally restricted Phe-Leu dipeptide mimetic to the design of a combined inhibitor of angiotensin I-converting enzyme and neutral endopeptidase 24.11. J. Med. Chem. 1993, 36, 2420-2423.
20. For a representative set of leading references on mercaptoacyl dipeptides and dipeptide mimetics, see: (a) Robl, J. A.; Cimarusti, M. P.; Simpkins, L. M.; Brown, B. B.; Ryono, D. E.; Bird, J. E.; Asaad, M. M.; Schaeffer, T. R.; Trippodo, N. C. Dual metalloprotease inhibitors 6. Incorporation of bicyclic and substituted monocyclic azepinones as dipeptide surrogates in angiotensin-converting enzyme/neutral endopeptidase inhibitors. J. Med. Chem. 1996, 39, 494-502 and references therin. (b) Fink, C. A.; Carlson, J. E.; McTaggart, P. A.; Qiao, Y.; Webb, R.; Chatelain, R.; Jeng, A. Y.; Trapani, A. J. Mercaptoacyl dipeptides as orally active dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase. J. Med. Chem. 1996, 39, 3158-3168 and references therin. (c) Fournie-Zaluski, M.-C.; Coric, P.; Thery, V.; Gonzalez, W.; Meudal, H.; Turcaud, S.; Michel, J.-B.; Roques, B. P. Design of orally active dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme with long duration of action. J. Med. Chem. 1996, 39, 2594-2608 and references therein. (d) Flynn, G. A.; Beight, D. W.; Mehdi, S.; Koehl, J. R.; Giroux, E. L.; French, J. F.; Hake, P. W.; Dage, R. C. Application of a conformationally restricted Phe-Leu dipeptide mimetic to the design of a combined inhibitor of angiotensin I-converting enzyme and neutral endopeptidase 24.11. J. Med. Chem. 1993, 36, 2420-2423.
21. For a representative set of leading references on mercaptoacyl dipeptides and dipeptide mimetics, see: (a) Robl, J. A.; Cimarusti, M. P.; Simpkins, L. M.; Brown, B. B.; Ryono, D. E.; Bird, J. E.; Asaad, M. M.; Schaeffer, T. R.; Trippodo, N. C. Dual metalloprotease inhibitors 6. Incorporation of bicyclic and substituted monocyclic azepinones as dipeptide surrogates in angiotensin-converting enzyme/neutral endopeptidase inhibitors. J. Med. Chem. 1996, 39, 494-502 and references therin. (b) Fink, C. A.; Carlson, J. E.; McTaggart, P. A.; Qiao, Y.; Webb, R.; Chatelain, R.; Jeng, A. Y.; Trapani, A. J. Mercaptoacyl dipeptides as orally active dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase. J. Med. Chem. 1996, 39, 3158-3168 and references therin. (c) Fournie-Zaluski, M.-C.; Coric, P.; Thery, V.; Gonzalez, W.; Meudal, H.; Turcaud, S.; Michel, J.-B.; Roques, B. P. Design of orally active dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme with long duration of action. J. Med. Chem. 1996, 39, 2594-2608 and references therein. (d) Flynn, G. A.; Beight, D. W.; Mehdi, S.; Koehl, J. R.; Giroux, E. L.; French, J. F.; Hake, P. W.; Dage, R. C. Application of a conformationally restricted Phe-Leu dipeptide mimetic to the design of a combined inhibitor of angiotensin I-converting enzyme and neutral endopeptidase 24.11. J. Med. Chem. 1993, 36, 2420-2423.
22. For a representative set of leading references on mercaptoacyl dipeptides and dipeptide mimetics, see: (a) Robl, J. A.; Cimarusti, M. P.; Simpkins, L. M.; Brown, B. B.; Ryono, D. E.; Bird, J. E.; Asaad, M. M.; Schaeffer, T. R.; Trippodo, N. C. Dual metalloprotease inhibitors 6. Incorporation of bicyclic and substituted monocyclic azepinones as dipeptide surrogates in angiotensin-converting enzyme/neutral endopeptidase inhibitors. J. Med. Chem. 1996, 39, 494-502 and references therin. (b) Fink, C. A.; Carlson, J. E.; McTaggart, P. A.; Qiao, Y.; Webb, R.; Chatelain, R.; Jeng, A. Y.; Trapani, A. J. Mercaptoacyl dipeptides as orally active dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase. J. Med. Chem. 1996, 39, 3158-3168 and references therin. (c) Fournie-Zaluski, M.-C.; Coric, P.; Thery, V.; Gonzalez, W.; Meudal, H.; Turcaud, S.; Michel, J.-B.; Roques, B. P. Design of orally active dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme with long duration of action. J. Med. Chem. 1996, 39, 2594-2608 and references therein. (d) Flynn, G. A.; Beight, D. W.; Mehdi, S.; Koehl, J. R.; Giroux, E. L.; French, J. F.; Hake, P. W.; Dage, R. C. Application of a conformationally restricted Phe-Leu dipeptide mimetic to the design of a combined inhibitor of angiotensin I-converting enzyme and neutral endopeptidase 24.11. J. Med. Chem. 1993, 36, 2420-2423.
23. Trippodo, N. C.; Robl, J. A.; Asaad, M. M.; Bird, J. E.; Panchal, B. C.; Schaeffer, T. R.; Fox, M.; Giancarli, M. R.; Cheung, H. S. Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin converting enzyme BMS-182657 in experimental hypertension and heart failure. J. Pharmacol. Exp. Ther. 1995, 275, 745-752.
24. (a) Baldwin, J. E.; Hulme, C.; Schofield, J.; Edwards, A. J. Synthesis of potential β-turn bicyclic dipeptide mimetics. J. Chem. Soc., Chem. Commun. 1993, 935-936.
25. (b) Cornille, F.; Slomczynska, U.; Smythe, M. L.; Beusen, D. D.; Moeller, K. D.; Marshall, G. R. Electrochemical cyclization of dipeptides toward novel bicyclic, reverse-turn peptidomimetics. 1. Synthesis and conformational analysis of 7,5-bicyclic systems. J. Am. Chem. Soc. 1995, 117, 909-917.
26. (c) Reference 15.
27. Robl, J. R. Peptidomimetic synthesis: Utilization of N-acyliminium ion cyclization chemistry in the generation of 7,6- and 7,5-fused bicyclic lactams. Tetrahedron Lett. 1994, 35, 393-396.
28. Robl, J. A. Compounds containing a fused multiple ring lactam. European patent application EP657453A.
29. Saponification of homochiral N-Cbz-L-homocysteine thiolactone under various conditions resulted in the formation of racemic 9 due to rapid epimerization of the chiral center. Thus the more readily available and less costly racemic homocysteine thiolactone was utilized in this procedure.
30. (a) Belyaev, A. A. A novel synthetic route to enantiomers of ε-hydroxynorleucine and ε-chloronorleucine from L and D,L-lysine. Tetrahedron Lett. 1995, 36, 439-440.
31. (b) Baldwin, J. E.; Killin, S. J.; Adlington, R. M.; Spiegel, U. Synthesis of N-benzyloxycarbonyl-L-α-aminoadipic acid, α-benzyl ester. Tetrahedron 1988, 44, 2633-2636.
32. 6-hydroxylysine. J. Am. Chem. Soc. 1982, 104, 3096.
33. We have also demonstrated that the corresponding dimethyl acetal of aldehyde 14, dipeptide 18, undergoes conversion to 15 in similar yield and diastereoselectivity (see scheme below). Compound 18 was prepared by coupling acetal 17 with the free acid of 9. Full experimental details may be found in the patent cited in ref 15. (Chemical Equation Presented)
34. N2 substitution using cesium thiocarboxylates. J. Org. Chem. 1986, 51, 3664-3671.
35. Experimental details outlining the synthesis of compounds 1a-e have been reported: Robl, J. R. US Patent 5,508,272, April 16, 1996. Compounds 1f and 1g were previously disclosed in an earlier report (ref 6a).
36. Krapcho, J.; Turk, C.; Cushman, D. W.; Powell, J. R.; DeForrest, J. M.; Spitzmiller, E. R.; Karanewsky, D. S.; Duggan, M.; Rovnyak, G.; Schwartz, J.; Natarajan, S.; Godfrey, J. D.; Ryono, D. E.; Neubeck, R.; Atwal, K. S.; Petrillo, E. W. Angiotensin-converting enzyme inhibitors. Mercaptan, carboxyalkyl dipeptide, and phosphinic acid inhibitors incorporating 4-substituted prolines. J. Med. Chem. 1988, 31, 1148-1160.
37. Robl, J. A.; Simpkins, L. M.; Sulsky, R.; Sieber-McMaster, E.; Stevenson, J.; Kelly, Y. F.; Sun, C. Q.; Misra, R. N.; Ryono, D.; Asaad, M. M.; Bird, J. E.; Trippodo, N. C.; Karanewsky, D. S. Dual metalloprotease inhibitors. II. Effect of substitution and stereochemistry on benzazepinone based mercaptoacetyls. Bioorg. Med. Chem. Lett. 1994, 4, 1795-1800.
38. A full description of the in vitro assays and the AI pressor, the 1K-DOCA salt rat, and sd-SHR assays can be found in ref 7.
39. Seymour, A. A.; Asaad, M. M.; Abboa-Offei, B. E.; Smith, P. L.; Mathers, P. D.; Rogers, W. L.; Dorso, C. R. Renal and depressor activities of inhibitors of neutral endopeptidase and angiotensin converting enzyme in monkeys infused with angiotensin II. J. Cardiovasc. Pharmacol. 1996, 25, 397-401.